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Sirtuins are known to slow aging in simple eukaryotes; however, viewing mammalian sirtuins as antiaging
proteins may be overly simplistic. In this issue of Cell Metabolism, Li et al. (2008) provide evidence that
SirT1 has properties consistent with both pro- and antiaging functions in mice.Sirtuins are a family of NAD-dependent
protein deacetylases and ADP ribosyl-
transferases homologous to the yeast si-
lent information regulator (SIR) 2 (Haigis
and Guarente, 2006; Longo and Kennedy,
2006). Over the past decade, sirtuins have
gone from a relatively uncharacterized
family of yeast proteins to some of the
most studied—and certainly the most
touted—targets of aging-related re-
search. Sirtuins are generally thought of
as prolongevity factors, based on the ob-
servation that increased expression of
Sir2 orthologs is sufficient to increase life
span in yeast, worms, and flies (Guarente
and Picard, 2005). It remains unknown,
however, whether the mammalian Sir2
ortholog, SirT1, has a similar longevity-
promoting role. In this issue, Li et al. ex-
amine effects resulting from inhibition of
SirT1. Surprisingly, they find that, al-
though life span is shortened, inhibition
of SirT1 also leads to cellular phenotypes
suggesting slower aging in the brain.
Sirtuins have received much celebrity
recently, based on the therapeutic poten-
tial of sirtuin activators. The appeal of sir-
tuins as antiaging drug targets was
elevated significantly by two related de-
velopments. First, studies carried out in
yeast led to the proposal that Sir2 acts
as a key downstream mediator of life-
span extension from dietary restriction
(Guarente and Picard, 2005). Dietary re-
striction, a reduction in nutrient availability
without malnutrition, is known to increase
life span in multiple organisms and to de-
lay theonset of a variety of age-associated
diseases in mammals. Second, the small
molecule resveratrol was identified as an
in vitro activator of Sir2 and was reported
to increase life span in yeast, worms, flies,
and one short-lived species of fish (Baur
and Sinclair, 2006). More recently, resver-
atrol has also been reported to protect
mice against negative health conse-4 Cell Metabolism 8, July 2008 ª2008 Elseviequences of a high-fat diet, an effect attrib-
uted by the authors to activation of SirT1
(Baur et al., 2006; Lagouge et al., 2006).
Unfortunately, what has often been lost
in reviews of the sirtuin literature and re-
ports in the popular media are the many
complexities and inconsistencies in our
understandingof sirtuinbiologyas it relates
to aging. For example, in yeast, Sir2 over-
expression increases replicative life span,
defined as the number of daughter cells
produced by a mother cell, but shortens
chronological life span, which is ameasure
of the length of time a yeast cell can survive
in a nondividing state (Fabrizio et al., 2005).
More perplexing is the observation that, al-
though Sir2 orthologs promote longevity in
yeast (replicative), worms, and flies, the
currently available data suggest that they
do so via different molecular mechanisms
in each of these organisms (Figure 1). Con-
sensus on several key questions related to
sirtuin biology in aging has been difficult to
achieve, aswell. For example,multiple labs
have reported that sirtuins are not always
required for life-span extension from die-
tary restriction in either yeast or worms
(Kaeberlein and Powers, 2007); the initial
reports of Sir2-dependent life-span exten-
sion from resveratrol in yeast, worms, and
flies has proven difficult to replicate (Bass
et al., 2007; Kaeberlein et al., 2005); and re-
sveratrol has been reported by different
labs to activate, inhibit, or have no effect
on sirtuins in vivo.
The situation regarding sirtuin biology
inmammals is particularly complex. In ad-
dition to SirT1, there are six other mam-
malian sirtuins of diverse function and
subcellular localization (Haigis and Guar-
ente, 2006). SirT1 itself has been reported
to deacetylate a plethora of substrates,
including histones, p53, Ku70, NF-kB,
PGC-1a, FOXO1, and PPARg (Haigis
and Guarente, 2006). Although most of
the SirT1 knockout mice are embryonicr Inc.lethal, the animals that survive appear rel-
atively normal. Interestingly, SirT1 knock-
out animals fail to show increased life
span in response to dietary restriction,
consistent with the hypothesis that the
life-span extension from dietary restric-
tion is mediated by activation of SirT1;
however, as Li et al. point out, this exper-
iment is difficult to interpret due to the
shortened life span of the SirT1 knockouts
on a normal diet. Similarly, in yeast, SIR2
deletion mutants are short lived and fail
to respond to dietary restriction; however,
Figure 1. Different Mechanisms of Sir2
Longevity Control in Evolutionarily
Divergent Organisms
(A) Sir2 slows yeast replicative aging by repressing
the formation of extrachromosomal rDNA circles
(ERCs), but accelerates chronological aging by
reducing activity of the alcohol dehydrogenase
encoded by ADH2.
(B) Sir-2.1 promotes longevity inC. elegansby regu-
lating the FOXO-family transcription factor Daf-16.
(C and D) The molecular mechanism(s) by which
dSir2 promotes longevity in flies remains unknown
(C), and the extent to which SirT1 influences aging
in mammals has yet to be determined (D).
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is suppressed by deletion of a second
gene, FOB1, mother cells respond ro-
bustly to dietary restriction and live
substantially longer than wild-type cells
(Kaeberlein et al., 2004).
Whatmakes the study by Li et al. partic-
ularly interesting is the observation that
SirT1 inhibition causes some phenotypes
more consistent with a slower rate of
aging. For example, they show that SirT1
inhibition leads to increased IRS-2acetyla-
tion, decreased IGF-1 signaling, and de-
creased Ras/ERK signaling. Decreased
Ras signaling increases life span in yeast,
and reduced insulin/IGF-1-like signaling
is associated with increased life span in
worms, flies, and mice. Supporting the
idea that inhibition of SirT1 may slow as-
pects of aging in mice, Li et al. proceed
to show enhanced resistance to oxidative
stress in neuronal cells after SirT1 knock-
down and reduced oxidation of proteins
and lipids in brains of SirT1 knockout ani-
mals. Taken together, these datamay indi-
cate that inhibition of SirT1 can be neuro-
protective in aging animals and that some
features of aging are slowed rather than
accelerated in SirT1 knockout animals.
So what’s the ‘‘take-home message’’
from all this? Is more SirT1 good, or is
less SirT1 good? The answer, as is oftenDiabetes Risk Beg
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Both intrauterine and postnatal envi
netic mechanisms underlying b cell
repressive histone modification and
initiate a disturbing epigenetic casca
The prevalence of childhood obesity
and type 2 diabetes (DM) has increased
dramatically in the past 50 years. While
overnutrition and a sedentary lifestyle
clearly contribute to these findings, the in-
trauterine and early postnatal environ-
ment are also key contributors to obesitythe case inbiology, is that there’s nosimple
answer.ActivatingSirT1 isprobablyagood
thing in some cells under some conditions
and is probably a bad thing in other cells
under other conditions. SirT1 activators
may be good for diabetes but may cause
cancer due to p53 inhibition, SirT1 inhibi-
tors may protect against cancer but cause
metabolic disease, and there is evidence
supporting the idea that both activators
and inhibitors of SirT1 can confer protec-
tion against neurodegeneration in different
contexts. The one thing that seems clear is
that sirtuin activators are unlikely to be
a ‘‘magic bullet’’ for aging. A more realistic
hope is that, as we continue to unravel the
complexitiesof sirtuinbiology, targetedac-
tivation or inhibition of SirT1—and perhaps
other sirtuins as well—will prove therapeu-
tically useful toward a subset of age-asso-
ciated diseases. Such an achievement
would be a huge step forward in the transi-
tion of aging-related science from the labo-
ratory to the clinic, and we eagerly await
the next chapter in the unfolding saga that
is sirtuin biology.
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